CureVac N.V. (ETR:5CV)
Germany
· Delayed Price · Currency is EUR 3.138
-0.062 (-1.94%)
Feb 21, 2025, 5:35 PM CET
CureVac Revenue
CureVac had revenue of 14.44M EUR in the quarter ending June 30, 2024, with 90.47% growth. This brings the company's revenue in the last twelve months to 65.86M, up 75.12% year-over-year. In the year 2023, CureVac had annual revenue of 53.76M, down -20.26%.
Revenue (ttm)
65.86M
Revenue Growth
+75.12%
P/S Ratio
n/a
Revenue / Employee
60.64K
Employees
1,172
Market Cap
708.26M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 22.67B |
| Merck KGaA | 20.96B |
| Bayer Aktiengesellschaft | 46.74B |
| Fresenius SE & Co. KGaA | 22.81B |
| Sartorius Aktiengesellschaft | 3.38B |
| Fresenius Medical Care AG | 19.24B |
| Carl Zeiss Meditec AG | 2.08B |
| SCHOTT Pharma AG & Co. KGaA | 954.68M |
CureVac News
- 4 days ago - CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World’s Top Innovators - Wallstreet:Online
- 4 days ago - CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators - Accesswire
- 4 days ago - CureVac: LexisNexis Names It a Global Innovation Leader Again! - Wallstreet:Online
- 4 days ago - EQS-News: CureVac Earns Repeat Recognition by LexisNexis as One of the World’s Top Innovators - Wallstreet:Online
- 6 weeks ago - Why CureVac (CVAC) Shares Are Volatile - Benzinga
- 6 weeks ago - CureVac: Latest GBM Data Bodes Well For Next Program Check Point - Seeking Alpha
- 6 weeks ago - Why CureVac (CVAC) Stock Is Moving - Benzinga
- 6 weeks ago - Vaccine makers’ shares jump after bird flu death in US - Financial Times